Parakeet Health raises $10M Series A to book more care with patient-access AI

Parakeet Health said Thursday it closed an oversubscribed $10 million Series A led by Canvas Ventures, bringing total funding to $13 million for an AI platform that turns inbound calls, outreach, fax, and web scheduling into booked appointments.

Clinics keep adding providers and still watch new-patient wait times climb, while no-shows and canceled slots leak revenue. Parakeet’s bet is that one agentic stack — software that runs phone, text, email, web, and fax as a single workflow — can turn that demand into booked care without a separate vendor for every channel, and Canvas led this $10 million round for a company already inside six of the ten largest U.S. dermatology groups.

On Thursday, 1 October 2026, Parakeet Health said it closed an oversubscribed $10 million Series A. A Series A is an early private funding round, named with a letter. Oversubscribed means more investors wanted in than the company took. Ten million dollars is the new money. Canvas Ventures led the round. Blank Space Ventures, StoryHouse Ventures, and HMC INQ participated. The round brings total funding to $13 million. Total funding is every dollar raised so far, including this round. Take $10 million off $13 million and the earlier raises add up to $3 million. That subtraction is arithmetic. The release does not name the earlier round or who led it. The dateline is San Francisco. The release went out on PR Newswire. The source line is Parakeet Health. Those lines are the release.

What the company says the year behind the round looked like. The funding follows 10x annual recurring revenue growth over the past year. Annual recurring revenue, shortened to ARR, is the yearly value of the customer contracts the company counts as ongoing. Ten times means the company says that figure is ten times what it was a year earlier. The release says the growth was driven by measurable financial returns for customers, and that Parakeet grew while keeping a disciplined approach to capital. Disciplined, in that sentence, is the company’s word for not spending the money loosely. The release does not print the dollar size of the revenue, and it does not print a valuation. A valuation is the price a round puts on the whole company. Those lines are Parakeet’s.

Where the new money goes, as the release states it. Parakeet will use the Series A to expand its technology and its team, advance personalization, support continued growth with enterprise healthcare organizations, and extend the platform across more specialties and more patient-engagement workflows. An enterprise customer, here, is a large group, not a single office. Personalization, as the release describes it later, means each interaction can change how, where, and when the system reaches the patient next, using communication preferences, prior responses, and care needs. The aim the release states is more interactions finished without staff, and a message that fits that patient. Those lines are the release.

What the platform does, in the release’s own account. Parakeet says it brings the ways patients communicate, and the steps they finish, into one platform. It manages inbound calls, proactive outreach, fax processing, and web scheduling across voice, text message, email, web, and fax. Because those pieces run together, a referral that arrives as a fax can move into outreach, scheduling, and follow-up in the same workflow, and each step shows up on one performance dashboard. The company says a clinic can replace several separate tools and give patients a more consistent experience at every touchpoint. The about box calls Parakeet a conversational agentic platform, powered by large language models, that handles inbound and outbound communication at scale. Agentic, here, means the software carries the access work through — it books, follows up, and moves a fax referral along — rather than only answering one question. A large language model is the kind of AI that reads and writes language. Those descriptions are Parakeet’s.

How it sits inside a clinic, as the release states it. The platform connects to the electronic health record and the practice-management system a group already uses. An electronic health record is the chart. Practice management is the system that runs the schedule and the office. The release says the software adapts to each organization. It can handle differences among providers, procedures, locations, insurance, and scheduling rules, find open clinical time, and connect the right patient with that time. The release does not name the chart systems. Those lines are the release.

Who Parakeet says it already works with. The company says it works with six of the 10 largest dermatology groups in the country, supporting more than 2,800 providers across 1,100 or more locations. Six of ten is a majority of that top group, on the company’s count. More than 2,800 providers is the clinician count it prints. The company says it is expanding into primary care, behavioral health, women’s health, eyecare, physical therapy, gastroenterology, and radiology. It also says it recently announced a national collaboration with Qualderm Partners, which supports nearly 160 practices across 17 states. Nearly 160 is the release’s figure for that group. The release does not say Qualderm is one of the six largest dermatology groups, and it does not print the date of that earlier announcement. Those lines are Parakeet’s.

The performance figures are Parakeet’s, and the release prints them as comparisons. A head-to-head pilot found that Parakeet’s inbound phone agent reached 2.3 times the resolution rate of an established AI voice vendor. A resolution rate, here, is how often a call gets to a finished outcome. The release does not define what counts as resolved, it does not name the other vendor, and it does not print how many calls were in the pilot. 2.3 times is a bit more than twice that other vendor’s rate, on Parakeet’s figure. On outbound work, the company says that across its deployments it rebooks no-show patients at up to 4.9 times higher rates, and canceled patients at up to 4.2 times higher rates, than leading patient-engagement vendors. Up to means the high end the company reports, not a result it says every clinic hits. A no-show is a patient who misses the visit. A cancellation is a visit that was called off. 4.9 times is nearly five times. 4.2 times is a bit more than four times. The release does not name those vendors either. The same section says the platform is built to create incremental revenue and to capture revenue that leaks out of disconnected access workflows. Incremental means bookings the clinic would not have had. Leakage, here, is the money that disappears when a slot stays empty or a patient never gets booked. Those comparisons are the company’s.

How a deployment is supposed to run, as the release states it. Parakeet says it works with leadership to model the possible effect on EBITDA, build the business case, set an evaluation, and prepare for the operating change. EBITDA is a profit measure operators use: earnings before interest, taxes, depreciation, and amortization. The release says the team models a potential impact. It does not print a dollar figure for that impact. Dedicated customer-success and engineering teams then configure the platform around the clinic’s workflows. The company says an enterprise deployment takes four to six weeks, with limited demands on the clinic’s own staff. It also says it uses a performance-based model tied to verified results: appointments booked, interactions resolved, and revenue generated. Performance-based means the fee is tied to those results, rather than only to a software seat. The release does not print the price. Those lines are Parakeet’s.

Three people are quoted on the release. Jung Park, chief executive and co-founder, said patient engagement decides whether demand becomes care, whether clinical capacity is used, and whether a healthcare organization grows. He said that after years of operating healthcare organizations, he saw that value lost across disconnected workflows, systems, and vendors. He said Parakeet was built to connect the whole journey and produce a financial result leadership can measure, and that the company applied the same operator discipline to its own growth. Julie Gessin, chief operating officer at Schweiger Dermatology Group, said Parakeet helps Schweiger Dermatology and Schweiger Allergy & Asthma patients get appointments when they need them. Rebecca Lynn, co-founder and managing director at Canvas Ventures, said the team combines AI experience with a record of winning large healthcare customers and delivering a measurable return. She said Parakeet is helping some of the country’s largest specialty groups book more appointments, lower costs, and make care easier to reach, and that patient engagement should be one connected AI experience across every channel rather than a pile of separate tools. Those quotations are theirs, in the release.

The release’s picture of the market around the round. It says nearly three in ten medical groups reported longer new-patient wait times in 2026, even as practices added providers, expanded hours, and made other changes to increase access. Three in ten is 30 percent. Nearly three in ten is a bit under that. The release also says AI now plays some role in patient visits at 83 percent of medical groups, up from 71 percent a year earlier. Eighty-three percent is a bit more than four in five. Seventy-one percent is a bit more than seven in ten. The twelve-point gap is the release’s comparison, one year to the next. The release does not name the survey behind either figure. It says healthcare groups are judging AI by whether it improves access, increases capacity, and produces a financial return, rather than by whether it automates one isolated task. Those lines are the release.

The about box lists who backs the company, and that list is wider than this round. It names Canvas Ventures, Blank Space Ventures, CoFound Partners, StoryHouse Ventures, HMC INQ, and individual investors. CoFound Partners is on that backers list. The Series A paragraph names Canvas, Blank Space, StoryHouse, and HMC INQ. The release does not say CoFound wrote a check in this round. The about box also says the founders come from healthcare and technology companies. It does not print those company names. The press contact on the release is press@parakeethealth.com.

The picture is Parakeet’s brand graphic. A cream field carries a green PARAKEET wordmark. The line under it reads “Convert patient demand into booked appointments.” A caption bar along the bottom reads “$10M Series A.” The graphic states the company’s claim and the size of this round. It does not print a calendar date.

In plain terms, Parakeet said on Thursday that Canvas Ventures led an oversubscribed $10 million Series A, with Blank Space Ventures, StoryHouse Ventures, and HMC INQ participating, and that total funding is now $13 million. The company says one AI workflow covers phone, text, email, web, and fax, so a faxed referral can become outreach, a booking, and a follow-up. It says it is already inside six of the ten largest U.S. dermatology groups, supporting more than 2,800 providers at 1,100 or more locations, and that a pilot’s inbound phone agent reached 2.3 times the resolution rate of an unnamed AI voice vendor. The no-show and cancellation comparisons are the company’s “up to” figures, 4.9 times and 4.2 times, against unnamed vendors. The release does not print a valuation, and it does not say the Food and Drug Administration cleared the platform.